IgG4-related disease: advances in pathophysiology and treatment.


Journal

Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248

Informations de publication

Date de publication:
05 2023
Historique:
medline: 26 4 2023
pubmed: 25 3 2023
entrez: 24 3 2023
Statut: ppublish

Résumé

IgG4-related disease (IgG4-RD) is a rare fibro-inflammatory disease affecting multiple organs. In recent years basic and translational research has unveiled the role of different cellular subtypes and cytokines in inducing and perpetuating the pathological process, eventually leading to fibrosis of affected tissues. Hopefully, the growing knowledge of the disease pathogenesis will lead to patient-tailored treatments in the near future. This review focuses on the most recent discoveries concerning the pathogenic mechanisms underlying IgG4-RD and highlights their potential role as specific therapeutic targets. IgG4-RD is a systemic and multifaceted disease. Its sensitivity to glucocorticoids is well known, however new targeted therapies are emerging that can reduce glucocorticoid exposure and achieve sustained clinical responses. Clinicians managing patients with such a rare and heterogeneous disease must therefore be aware of its varied phenotype and traditional and novel therapeutic strategies.

Identifiants

pubmed: 36960748
doi: 10.1080/1744666X.2023.2195627
doi:

Substances chimiques

Immunoglobulin G 0
Glucocorticoids 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

537-547

Auteurs

Francesco Peyronel (F)

Nephrology and Dialysis Unit, Meyer Children's University Hospital - IRCCS, Firenze, Italy.
Department of Experimental and Clinical Medicine, University of Fireze, Firenze, Italy.

Paride Fenaroli (P)

Nephrology and Dialysis Unit, Azienda USL - IRCCS Reggio Emilia, Reggio Emilia, Italy.

Federica Maritati (F)

Nephrology, Dialysis and Renal Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Alma Mater Studiorum University of Bologna, Bologna, Italy.

Nicolas Schleinitz (N)

Internal Medicine Department Hôpital La Timone, APHM, Aix Marseille University, Marseille, France.

Augusto Vaglio (A)

Nephrology and Dialysis Unit, Meyer Children's University Hospital - IRCCS, Firenze, Italy.
Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Firenze, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH